Titre :

Patterns of response to crizotinib in recurrent glioblastoma according to alk and met molecular profile in two patients

Auteur(s) :

Le Rhun, Emilie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Chamberlain, Marc C. [Auteur]
Zairi, Fahed [Auteur]
Delmaire, Christine [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Idbaih, Ahmed [Auteur]
Renaud, Florence [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172

Maurage, Claude-Alain [Auteur]

Lille Neurosciences & Cognition (LilNCog) - U 1172
Gregoire, Valerie [Auteur]

Titre de la revue :

CNS oncology

Nom court de la revue :

CNS Oncol

Numéro :

4

Pagination :

381-6

Date de publication :

2015-01-01

ISSN :

2045-0915

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Two patients with an unmethylated MGMT promoter and IDH1 (R132H) wild-type recurrent glioblastoma were treated with crizotinib. Prolonged stabilization of the disease (17 months) was achieved in the first case. Interestingly, ...
Lire la suite >Two patients with an unmethylated MGMT promoter and IDH1 (R132H) wild-type recurrent glioblastoma were treated with crizotinib. Prolonged stabilization of the disease (17 months) was achieved in the first case. Interestingly, anaplastic lymphoma kinase (ALK) expression and c-MET protein overexpression was observed. Conversely, no response to crizotinib was obtained in the second case with MET protein overexpression and c-MET amplification but no ALK expression or ALK gene amplification. These case studies suggest that novel targeted ALK inhibitors may provide relevant clinical benefit in selected cases in which driver mutations are demonstrable.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
CNRS
INSERM
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172
• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Date de dépôt :

2019-11-27T13:33:33Z
2023-04-21T10:35:55Z